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Abstract: The U.S. population is chronically exposed to a wide variety of environmental 
chemicals, including organophosphorus pesticides (OPs) such as chlorpyrifos. 
Chlorpyrifos oxon (CPO), the active metabolite of chlorpyrifos, inhibits 
acetylcholinesterase (AChE) to elicit toxicity, but is also a potent inhibitor of fatty acid 
amide hydrolase (FAAH). FAAH plays an important role in the degradation of fatty acid 
signaling lipids, and is the key enzyme in terminating endocannabinoid (eCB) signaling 
by hydrolyzing N-archidonylethanolamine (anandamide, AEA). AEA and other lipid 
intermediates, such as the eCB-like metabolites oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA), are potent agonists at peroxisome proliferator-activated 
receptors (PPAR). PPARs regulate genes involved in numerous physiological processes 
associated with lipid metabolism and energy homeostasis. We hypothesized that 
inhibition of FAAH by CPO would disrupt degradation of intracellular AEA and OEA, 
leading to increased PPAR transcriptional activity, and altered expression of PPAR target 
genes. To evaluate the effects of CPO on PPAR-mediated gene expression, we exposed 
MCF-7 cells to a range of CPO concentrations in culture. In vitro inhibition assays were 
first conducted to evaluate concentration-dependent inhibition of FAAH and, for 
comparison, AChE.  Cell cultures were then exposed to one of three selected CPO 
concentrations either alone, or along with AEA or OEA. Samples were collected at 8 
hours, 1 day, and 3 days after dosing for gene expression analysis. Changes in expression 
of four selected target genes coupled to PPAR activation were measured using real-time 
quantitative polymerase chain reaction, and the comparative Ct method to quantify fold 
change in expression. Our results demonstrated inhibition of FAAH and AChE, as well as 
upregulation of all four target genes in a concentration and time-dependent manner. 
Inclusion of either AEA or OEA with CPO generally decreased the extent of gene 
upregulation noted with CPO alone. These are the first data to suggest that exposure to 
chlorpyrifos could influence lipid metabolism through PPAR activation, potentially 
contributing to metabolic disorders including obesity. 
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Chronic exposure to biologically active environmental contaminants is something 
that is unavoidable. Despite some of their known toxicological effects, many such 
contaminants exist in our home, in the workplace, and in our food and water sources, just 
to name a few. For example, organophosphorus compounds are used in many forms that, 
are not only useful, such as in plasticizers,  but also those designed to keep us safe, such 
as flame retardants and pesticides created to protect our food crops (1).  
An organophosphorus compound (OP) is defined as any member of a group of 
organic compounds containing a phosphorus atom. Originally, OP synthesis was carried 
out with the goal of creating new, effective pesticides for the protection of food crops 
from insect infestation (1,2). Tetraetylpyrophosphate (TEPP) was the first commercially 
available OP insecticide, first synthesized circa 1854 (3). The first OP chemical weapon 
was synthesized in December of 1936. While working to create a new formulation of an 
OP insecticide, due to the shortage of the common insecticide of the time, nicotine, 
German scientist Gerhard Schrader accidentally made tabun (Ethyl 




Two additional G-agents (sarin and soman) were synthesized by the same group shortly 
after, which were followed by a second generation of nerve agents, known as the V-
agents (V for venom) (4). The focus on creating more effective weapons for some years 
gave way to a decline in OP pesticide synthesis. However, after the publication of “Silent 
Spring” by Rachel Carson in 1962, which ultimately led to the ban of the popular and 
widely used organochlorine insecticide DDT, it became necessary to find new chemicals 
to control insect pests. Once again, OPs became the most popular candidates for research 
and development in this capacity. In 1965, Dow AgroSciences got market the now 
common insecticide chlorpyrifos.  
 Chlorpyrifos (CPF; O,O’-diethyl-3,5,6-trichloropyridinyl-phosphorothioate) is 
one of the most extensively used insecticides worldwide, although it has been banned for 
residential use in the United States (5). It remains extensively used in industrial 
agriculture.  Additionally, it is used for protection of non-structural wood products, to 
combat insects that pose a threat to public health, such as municipal mosquito control 
spraying, and is actually the most frequently applied insecticide on golf courses. Its broad 
spectrum efficacy as an insecticide, combined with cost-effective availability, and user-
friendly ease of application, has made chlorpyrifos a popular pesticide for a variety of 
purposes.  Although risks to non-target organisms, including humans, have been 
extensively studied for safety and regulatory reasons, potential adverse effects of 
environmental exposure to chlorpyrifos remains a topic of concern for public health 
(4,6,7).  
 For humans, routes of exposure to chlorpyrifos include dermal, inhalation, and 
ingestion, with ingestion being the major route of entry (8). Only after chlorpyrifos has 
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been absorbed it is metabolically converted to its highly reactive metabolite, chlorpyrifos 
oxon, through oxidative desulfuration (9).  Figure 1 illustrates this reaction. If one 
consumes produce containing chlorpyrifos residues, the parent insecticide is converted to 
the oxon in the liver or other organ, which is roughly 1,000 times more potent than the 
insecticide itself (9).  
 
Figure 1. Bioactivation of chlorpyrifos to chlorpyrifos oxon. 
The acute toxicity of OPs is associated with the inhibition of the enzyme 
acetylcholinesterase (AChE). Acetylcholinesterase is the enzyme responsible for the 
regulation of signaling between neurons and other cells mediated by the neurotransmitter, 
acetylcholine.       Extensive AChE inhibition blocks acetylcholine inactivation at 
cholinergic synapses throughout the nervous system, leading to prolonged activation of 
cholinergic receptors and signs of cholinergic toxicity (10). Cholinergic toxicity is a 
result of excessive and prolonged activation of cholinergic receptors following AChE 
inhibition (11). Typical signs and symptoms of acute cholinergic toxicity include blurry 
vision, vomiting, diarrhea, convulsions, muscle twitching, and respiratory failure, the 
ultimate cause of death. Like other OPs, the “target” enzyme for acute CPF toxicity, is 
acetylcholinesterase (AChE). Alternative, non-cholinesterase macromolecular targets for 
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OPs have been the subject of investigation for decades, however, that could potentially 
participate in modulation of the toxicity of AChE inhibition as well as contribute to non-
cholinergic toxicity pathways (12,13). For example, AChE is a serine hydrolase and a 
number of other serine hydrolases have been shown to be sensitive to inhibition by OPs 
(13,14). One other serine hydrolase that is sensitive to in vivo inhibition by CPF (as well 
as in vitro inhibition by CPO) is fatty acid amide hydrolase (15). 
 Fatty acid amide hydrolase (FAAH) is an important regulator of signaling 
pathways in a variety of physiological functions including sleep induction, analgesia, and 
energy homeostasis (16). Numerous studies have reported that FAAH is a secondary 
target of action of several OPs (17–19). CPO and other OPs inhibit FAAH via covalent 
binding to its active site serine residue within the catalytic triad, which is essentially the 
same mechanism by which CPO inhibits AChE (20). Of particular importance is that 
FAAH is the primary enzyme involved in the inactivation of the endocannabinoid 
anandamide (N-arachidonoylethanolamine, AEA) and the endocannabinoid-like 
metabolites, palmitoylethanolamide (PEA) and oleyoylethanolamide (OEA) (21). 
 Humans have been using cannabinoids for thousands of years for medical, 
religious, and (likely only relatively recently) recreational purposes. The cannabis plant 
(C. sativa, C. indica) contains a large number of cannabinoids including the psychotropic 
compound delta 9-tetrahydrocannabinol (THC) (22,23). The discovery of a specific G 
protein-coupled receptor, the cannabinoid CB1 receptor that bound with high affinity to 
THC in the late 1980s, and subsequent discovery of endogenous ligands initiated the 
characterization of the endogenous cannabinoid (endocannabinoid) signaling pathway 
(17,24). Since that time, another specific cannabinoid receptor (CB2) was identified and 
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interactions between the endocannabinoids and endocannabinoid-like metabolites with 
these and other receptors have been described. Together, these many studies have shown 
the role of endocannabinoids in modulation of nervous (primarily through CB1 receptors) 
and immune (primarily through CB2 receptors) function (25,26).  
 The endocannabinoid (eCB) system constitutes a global neuromodulatory network 
that regulates neurotransmitter release at neuron presynaptic terminals (27). The receptors 
(mainly CB1), along with endocannabinoids, and the enzymes responsible for both their 
biosynthesis and degradation, make up this pathway. Endocannabinoid signaling is 
important in a number of neurological functions including appetite regulation, pain 
perception, cognitive development, emotional state, seizures and many others (25,28). 
The eCB system also plays an important role in lipid homeostasis and energy balance. 
The two primary eCBs (AEA) and 2-arachidonoylglycerol (2-AG), are synthesized “on 
demand” from membrane phospholipids following neuronal depolarization (26,29). The 
eCB AEA and the eCB-like metabolites OEA and PEA are capable of binding to and 
activating peroxisome proliferator-activated receptors, potentially influencing the 
expression of their target genes (30). 
 Peroxisome proliferator-activated receptors (PPARs), which form a subfamily of 
the nuclear receptor superfamily, are ligand-regulated transcription factors linked to the 
regulation of genes involved in several pathways of lipid metabolism include fatty acid 
oxidation, lipid transport, lipogenesis, and cholesterol metabolism, making PPARs 
essential components of energy homeostasis (31,32). Although there are three identified 
PPAR isoforms (PPARα, PPARγ, and PPARβ/δ), for the current study we chose to focus 
on two:  PPARα and PPARγ. 
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 As a major regulator of metabolic functions in the liver, PPARα expression is 
high in hepatocytes, where it has important roles in fatty acid oxidation, triglyceride 
clearance, cholesterol homeostasis, and lipoprotein production (33).  PPARγ is also 
expressed in liver tissue, although it is predominately located in adipose tissue, where it 
plays a major role in adipocyte differentiation (32,33). PPARγ-induced lipogenesis is not 
limited to fat cells. It also helps regulate which cells differentiate into myelin, which is 
essential for normal function of myelinated axons (32,33). In order for PPAR to regulate 
target gene expression, they first dimerize with the retinoid X receptor (RXR, another 
nuclear receptor) which subsequently binds to specific peroxisome proliferator response 
elements (PPREs) (34). The heterodimer formation with RXR requires binding of a 
PPAR agonist, which changes the conformation of the PPAR in a manner that allows for 
the heterodimerization to occur. AEA, PEA and OEA, are all PPAR agonists that can 
bind to PPARs, allowing the heterodimer formation and binding to the PPRE and leading 
to PPAR transcriptional activity. Figure 2 illustrates the heterodimer formation and 
binding to the PPRE. 
 
Figure 2. Endocannabinoid binding to PPAR alters the conformation, allowing for 




 In addition to concern over the adverse effects of OP pesticides, such as 
chlorpyrifos, in terms of its effects on cholinergic signaling, numerous other pathways of 
possible OP toxicity have been subjects of investigation for the last couple of decades 
(20,35). These studies include effects of pre-natal and juvenile exposure on neurological 
and cognitive development, as well as neurodegenterative diseases among other 
physiologic pathologies affecting older adults, and psychological disorders that effect 
behavior, learning, and response to stressors (36–38).  Many investigations have 
suggested that adverse outcomes can be associated with levels of exposure below those 
which inhibit acetylcholinesterase (35,39). Furthermore, there is a growing concern for 
chronic effects on metabolic function that may lead to issues related to heart disease, 
diabetes, and obesity (5,40).  Multiple studies have demonstrated that exposure to 
chlorpyrifos oxon causes weight gain in both juvenile and adult rats, as well as altered 
metabolic functions related to lipid homeostasis in prenatally exposed mice (12,39,41). 
The results of such studies suggest that exposure to environmental chemicals like OP 
pesticides are possible contributors to the ever increasing incidence of metabolic 
disorders in humans (5,42). 
 The obesity epidemic in the United States has continued to expand over the last 
several decades, affecting all age groups including young children, adolescents, and 
adults (43,44). Although inactivity, dietary habits, and genetic predisposition are all 
factors contributing to current trends, they are still not sufficiently enough to adequately 
explain the continuously increasing percentages of obesity throughout the population 
(42,45). It can be postulated that exposure to environmental chemicals is a possible 
contributing cause to the growing obesity epidemic considering that, in addition to acute 
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exposures, the population of the U.S. is exposed chronically to a wide variety of 
environmental chemicals that are used to protect food crops and commercial, residential, 
and industrial buildings from pest infestations (46). These chemicals include insecticides, 
such as chlorpyrifos. We hypothesized that exposure to OPs such as chlorpyrifos may 
lead to downstream changes in the expression of PPAR target genes involved in the 
regulation of lipid metabolism by inhibiting FAAH, increasing AEA and/or PEA and 
OEA which increases PPAR activation and alters lipid metabolism-related genes. 
 There are three important steps that help to define the processes involved in 
transcriptional regulation of lipid metabolism: 1) Upstream events that define the 
signaling, 2) molecular mechanisms that control the operation of transcription factors, 
and 3) downstream events that affect the target genes (47). Disruption of normal PPAR 
signaling can lead to a number of potentially adverse effects associated with dysregulated 
gene expression, including increased lipogenesis, insulin desensitization, dysfunctional 
cholesterol metabolism, faulty lipid transport mechanisms, and excess energy storage in 
the form of fat (48–50). The objective of this study was to evaluate the possible role of 
CPF as a contributing factor to altered metabolism and obesity. Although a number of 
studies have associated an OP exposure with increased body fat, and that show OPs such 
as chlorpyrifos can be potent inhibitors of FAAH, none have characterized potential 
changes in PPAR signaling as a consequence of the OP induced inhibition of FAAH, 
creating a direct link between exposure to organophosphorus pesticides and obesity. 
 To evaluate CPO’s effect on FAAH and PPAR signaling, we compared the in 
vitro concentration-dependent effects of CPO on FAAH and AChE activity, as well as on 
PPAR signaling in the MCF-7 human breast cancer cell line. This cell line was chosen 
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based on species relevance for extrapolation, the presence of both “target enzymes”, the 
presence of both PPAR subtypes, as well as functional PPAR signaling pathways (51). 
Four genes that are regulated by PPARs were selected based on their role in the 
regulation of lipid metabolism, and for their known expression in the MCF-7 cell line 
(51). 
 The liver X receptor alpha (LXRα), like the PPARs, is also a member of the 
nuclear receptor superfamily, and is a transcription factor involved in the regulation of 
genes responsible for multiple cellular functions associated with nutritional regulation 
and lipid metabolism (52). As a key regulator of hepatic cholesterol metabolism, LXRα is 
predominantly expressed in the liver, but is also expressed in adipose tissue, spleen, 
kidneys, macrophages, and the small intestine, where it serves as a primary regulator of 
intestinal cholesterol absorption (52). Interestingly, LXRα shares RXR as an obligate 
heterodimer partner with PPARs, and it has been demonstrated that LXRα and PPARα 
have a unique dynamic in their interaction as reciprocal regulators of nutritional fatty acid 
metabolism (53). Although LXRα was chosen primarily as a target for PPARα, it has 
been recently found that its expression is also regulated by PPARγ (53). Acyl-CoA 
oxidase (ACOX) was also selected as a target gene of PPARα. Human ACOX1 is highly 
expressed in the liver, as well as skeletal muscle and the kidneys. It is the first, and rate 
limiting, enzyme in the fatty acid β-oxidation pathway (54,55). 
 The genes selected in which expression is primarily regulated by PPARγ were 1-
acylglycerol-3-phosphate-O-acyltransferase (AGPAT2), and a member of the ATP-
binding cassette transporter super family, ABCG2. AGPAT2 belongs to the enzyme 
family of acyltransferases, and plays an important role in the biosynthetic pathway for 
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triaglycerols and glycerophospholipids (56,57). It is expressed primarily in adipose 
tissue, but is also found in the liver and pancreas. In fact, ABCG2 was originally 
identified as an overexpressed protein in the MCF-7 cell line (58). ABCG2 is expressed 
ubiquitously, but is most abundant in the liver, intestines, central nervous system, and the 
placenta. Substrates for ABCG2 include a wide variety of both endogenous and 
exogenous compounds (58,59). It is the ability of ABCG2 to transport such a diverse 
range of substrates that makes it a critical component of xenobiotic metabolism, as it 
plays a protective role against absorption of toxicants in barrier tissues, and facilitates 
clearance in organs such as the liver (59). 
 The specific aims of this study were as follows: 
1. Measure the amount of FAAH inhibition by CPO. 
2. Determine concentration dependent effects of CPO inhibited FAAH on exogenous 
agonists. 
3. Assess changes in expression of PPARα and PPARγ target genes in cells exposed to 
the concentrations of CPO, and exogenous agonists co-administered with those 










Chemicals and Reagents 
 Eagle's Minimum Essential Medium and fetal bovine serum were purchased from 
Quality Biological Inc.  Chlorpyrifos oxon (CPO, >97% purity) was purchased from 
Chem Service and kept desiccated under nitrogen at -70C. The desiccator containing 
CPO was brought to room temperature under the fume hood before opening to minimize 
any CPO hydrolysis. Eagle’s Minimum Essential Medium, fetal bovine serum, and 
DMSO were all purchased from ATCC. 5- amino-2-methoxypyridine was purchased 
from Sigma-Aldrich. Octanoyl methoxypyridine and was a kind gift from Dr. Bruce 
Hammock, UC Davis. TaqMan gene expression assays, TaqMan Fast Advanced Master 
Mix No AMP Erase UNG, and the High Capacity cDNA Reverse Transcription Kit were 
all purchased from Applied Biosystems. Anandamide and oleyoyl ethanolamide were 
both purchased from Cayman Chemical. Pioglitazone was obtained from Adipogen, and 




 Human MCF-7 cells were obtained from American Type Culture Collection 
(ATCC, HTB-22). Cells were initially seeded in 25 cm2 flasks, and sub-cultured at a ratio 
of 1:3 once a confluency of ~90% was reached. Cultures for chemical exposure, or assay 
use, were seeded at a density of ~ 4.2 x 106 cells per 60 mm plate in 4 mL complete 
culture medium (Eagle's Minimum Essential Medium, 10% FBS, insulin (human 
recombinant) 0.01 mg/mL). Cells were incubated at 37°C in 5% CO2 until they formed 
an adherent layer (generally 24-36 hours). Prior to any treatments, plates were removed 
from the incubator and the medium was aspirated before any chemical exposures. All 
chemicals were provided in fresh complete medium. 
 
Enzyme Assays 
Sample Collection and Preparation 
 The sample collection and preparation was performed the same way for all 
enzyme assays. At each time for collection, plates were removed from the incubator, 
medium aspirated, and the cells were rinsed three times with 1 mL ice-cold PBS. Lysates 
were made by adding 0.5 mL ice-cold lysis buffer (1 mL 50 mM EDTA, 25 mL 50 mM 
Tris HCl pH 7.4, 50 uL Triton X-100, 7.5 mL 1 M NaCl, and deionized water added to 
50 ml final volume) to each plate, followed by incubation on a bed of ice for 10 minutes. 
A cell scraper was used to detach any remaining, adherent cells and each lysate was 
transferred to a pre-chilled culture tube on ice. Each lysate was kept on ice and 
homogenized for 30 seconds using an Eberbach Con-Torque tissue homogenizer, then 
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transferred to pre-chilled Eppendorf tube (1.5 ml). Tubes were then centrifuged at 12,000 
x g for 15 minutes at 4°C. The supernatant was removed and transferred to a clean pre-
chilled Eppendorf tube and the pellet discarded. The supernatants were kept at -80°C 
until use. 
Total Protein Quantitation 
 Prior to performing any enzyme inhibition assays, it was necessary to measure the 
activities of AChE and FAAH in cell lysate over a range of protein concentrations. The 
supernatants collected, as described above, were thawed on ice. Serial dilutions of the cell 
lysate were made using the lysis buffer. Total protein for each dilution was quantified 
using the method described by Bradford (60). A standard curve was created using bovine 
serum albumin (BSA) (Sigma) diluted in the lysis buffer for a range of concentrations 
from 0.14 mg/mL to 1.14 mg/mL protein. Lysis buffer was used in the plate blank wells. 
Each well contained 4 uL of sample (or buffer for blanks) and 200 uL Bradford Reagent 
(Sigma) for a total reaction volume of 204 uL per well. All blanks and sample dilutions 
were loaded as quadruplicate replicates. The plate was incubated in the drawer, away 
from light, for 10 minutes prior to reading. Absorbance at 595 nM was read using a 
SpectraMax 340PC plate reader (Molecular Devices). The average optical density (OD) 
for each sample dilution was then compared to that of the BSA standard curve and the 
mg/mL protein interpolated using GraphPad Prism 6. 
Enzyme Activity 
AChE activity was measured using a method similar to that described by Ellman 
(61). Plates were prepared on ice by first adding 25 uL of sample dilution to wells, in 
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replicates of 4. Lysis buffer was used for plate blank wells. A DTNB-substrate cocktail 
(10 mM Tris buffer pH 7.2, 1 mM EDTA, 7.62 mM acetylthiolcholine,  1.086 mM 
DTNB) was mixed shortly before loading into the plate. Each well contained 175 uL of 
the DTNB-substrate cocktail for a total reaction volume of 200 uL. Once loaded, the 
plates were immediately placed into the SpectraMax 340PC plate reader. Activity was 
measured kinetically at 412 nM, reading once every 60 seconds for 10 minutes.  
 FAAH activity was measured by following a fluorometric method described by 
Huang et al. (15).  A 10 mM stock solution of the substrate octanoyl methoxypyridine 
(OMP), to produce a final concentration of 500 uM in the plate wells, was prepared in 
advance by dissolving the OMP in a 1:1 mixture of DMSO/EtOH. The substrate solution 
was kept stored at 4o C, away from light. Black, 96-well fluorometric plates were 
prepared on ice. Sample wells contained 30 uL of cell lysate and the plate blank wells 
contained 30 uL lysis buffer in place of the cell lysate. A range of concentrations  100 nM 
to 5000 nM of 5-amino-2-methoxypyridine (AMP) was used to generate a standard curve 
within each plate run. Samples were put in the plates as replicates of 4, AMP standards 
were loaded as duplicates. Plate blank and AMP standard wells contained 10 uL of 1:1 
DMSO/EtOH in place of the OMP substrate. Assay buffer, a solution of 125 mM sodium 
phosphate, pH 8, 1% glycerol, 0.1% Triton X – 100, was added to all wells for a total 
reaction volume of 200 uL. The OMP/EtOH/DMSO (10 uL) was added to the sample-
containing wells immediately before loading the plates into a BMG Labtech CLARIOstar 
plate reader. Plates were read for 10 minutes, with fluorescence (excitation: 320 nM, 
emission: 396 nM) measured every 60 seconds, and results given in terms of relative 
fluorescence units (RFUs), based on the hydrolysis of OMP to AMP. 
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Enzyme Inhibition Assays – Supernatant Treated 
 For initial measurements of AChE and FAAH inhibition, cells were collected and 
samples prepared as described above. The supernatants were thawed on ice, then 
incubated for 20 minutes in a 37o C water bath, with shaking, with various concentrations 
of chlorpyrifos oxon diluted in Tris-E, 1% EtOH.  Concentrations used were 5 nM, 10 
nM, 30 nM, 50 nM, 100 nM, 500 nM, and 1 uM. For the control sample, cell lysate was 
incubated with Tris-E, 1% EtOH. Activities were measured then using the same methods 
as described above for the respective enzyme. Additional FAAH inhibition assays were 
performed under the same conditions, using the same methods, but by adding complete 
culture medium to the incubation mixtures, to investigate whether, or not, the fetal bovine 
serum in the culture medium would interfere with CPO’s ability to inhibit FAAH. The 
results from the FAAH inhibition assays that included complete culture medium were 
used to decide which concentrations of CPO would be used to treat cell cultures for the 
measurement of gene expression changes.  
Enzyme Inhibition Assays - Cells Treated in Culture 
 The treatment method for enzyme inhibition using cells exposed while in culture 
was the same for both AChE and FAAH assays. Once ready for treatment, cells were 
removed from the incubator, medium aspirated. Cultures were given fresh complete 
medium containing CPO at concentrations of 250 nM, 500 nM, 1 uM, 2 uM, 3 uM, or 5 
uM in DMSO. Vehicle only treated cells (control) were given complete medium with a 
1% DMSO concentration, and all CPO treated plates also had a final DMSO 
concentration of 1% in the medium. Cells were collected at 8 hours, 1 day, and 3 days 
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post-exposure using the cell collection and sample preparation methods described above. 
Enzyme activities for AChE and FAAH were then measured using the respective 
methods as described above, as well.  
Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR) 
 Treatments for measurement of gene expression changes were as follows: vehicle 
only (DMSO) for reference control samples, 250 nM CPO, 500 nM CPO, 1 uM CPO, 
OEA, AEA, OEA + 250 nM CPO, OEA + 500 nM CPO, OEA + 1 uM CPO, AEA + 250 
nM CPO, AEA + 500 nM CPO, AEA + 1 uM CPO. Clofibrate and pioglitazone were 
used for positive controls as agonists at PPARα and PPARγ, respectively. All had a final 
DMSO concentration of 1%. Cells were exposed for 8 hours, 1 day, or 3 days.  
RNA Isolation 
At the post-exposure collection times, culture plates were removed from the incubator, 
and medium was aspirated. 1 mL Trizol reagent (Invitrogen) was added to each plate to 
lyse the cells. The mixture was homogenized in the plate by pipetting up and down three 
times before being transferred to a 1.5 mL Eppendorf tube. Tubes containing the cells in 
Trizol were left to incubate 5 minutes at room temperature, to allow time for complete 
dissociation of the nucleoproteins. 200 uL of chloroform was then added to each tube. 
Tubes were vigorously vortexed for 15 seconds, then incubated at room temperature for 3 
minutes. Samples were then centrifuged for 15 minutes at 12,000 x g, 4o C. After 
centrifugation, the aqueous phase was removed and transferred to a fresh 1.5 mL 
Eppendorf tube, the rest was discarded. To precipitate the RNA, 500 uL isopropanol was 
added to each tube and mixed by inversion. The tubes were incubated at room 
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temperature for 10 minutes prior to centrifugation at 12,000 x g, 4o C for 10 minutes. The 
supernatant was then removed from each tube, and pellets were washed by adding 1 mL 
75% ethanol to each tube, vortexed gently, then centrifuged again for 5 minutes at 7500 x 
g, 4o C. After washing, ethanol was removed from the tubes and pellets were air dried for 
10-15 minutes. Each pellet was re-suspended in 20 uL RNase-free water, then incubated 
for 15 minutes on a heat block set to 60o C. Total RNA was quantified by the absorbance 
method (A260/A280 ratio) using a Beckman Coulter DU530 UV/Vis spectrophotometer. 
RNA samples were stored at -70o C until used for cDNA synthesis.  
cDNA Synthesis 
RNA samples were removed from the -70o C freezer and thawed on ice. Applied 
Biosystems High Capacity cDNA Reverse Transcription Kit was used for cDNA 
synthesis. Kit components were thawed on ice, then mixed according to the 
manufacturer’s protocol. Reactions were carried out in 0.5 mL RNase-free tubes.  Tubes 
were prepared on ice by adding 10 uL of the reverse transcription master mix to 10 uL of 
RNA template, for a total reaction volume of 20 uL in each tube. Contents were mixed by 
pipetting before tubes were sealed. Tubes were centrifuged for 4 minutes at 2500 x g, 4o 
C before being placed into the thermal cycler (Eppendorf Mastercycler Gradient). The 
thermal cycling conditions were set at 25o C for 10 minutes, 37o C for 120 minutes, 85oC 
for 5 minutes, 4o C for 120 minutes. After completion of the thermal cycling protocol, 






 RT-qPCR reactions were carried out in an Applied Biosystems 7500-Fast Real 
Time PCR System. Thermal protocol settings, as specified by the manufacturer for 
TaqMan Fast Advanced Master Mix, were UNG incubation 50o C for 2 minutes (1 cycle), 
enzyme activation 95o C for 20 seconds (1 cycle), denature 95o C 3 seconds (40 cycles), 
and anneal/extend 60o C for 30 seconds (40 cycles). Experiments were set up in the 
system software as comparative Ct, using the vehicle treated samples as reference, and β-
Actin as the endogenous control. Plate layouts were entered prior to preparation. Each 
sample type and target gene for each sample type was run as triplicates. No treatment 
controls (NTCs) for blanks contained nuclease-free water in place of cDNA. The dyes in 
each reaction mix were FAM (reporter), NFQ-MGB (quencher), and ROX (passive 
reference). Reactions were set as two-step, singleplex.  
 Prior to plate preparation, all equipment and surfaces were cleaned with RNase-
Zap wipes. The TaqMan assay tubes containing the primers and probes for each target 
gene, and the cDNA samples were all thawed on ice. Primer sequences are listed in Table 
1. The primer/probe tubes were kept covered to protect from light while thawing. 
Reaction mixes were prepared according to the manufacturer’s protocol for TaqMan gene 
expression assays, then loaded into 96-well fast optical plate, with a final reaction volume 
of 20 uL in each well. The plates were kept on a cold block while loading samples and 
reaction mixes into the wells. Once loaded, the plates were sealed with optical adhesive 
film, then centrifuged for 4 minutes at 2500 x g, 4o C to remove bubbles and ensure that 
all contents were at the bottom of the wells. After centrifugation, plates were immediately 
placed into the PCR machine, and run started.  
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Gene Symbol NCBI RefSeq Primer (5’ – 3’) 
β-Actin NM_001101.3 CCCAGGCACCAGGGCGTGATGGTGG 
LXRα (NR1H3) NM_001130101.2 TTTGCCAAAGCAGGGCTGCAAGTGG 
ABCG2 NM_001257386.1 GGAGGCAAATCTTCGTTATTAGATG 
ACOX1 NM_001185039.1 AGCAGAGGTCCACGAATCTTACAAG 
AGPAT2 NM_001012727.1 GGTGGAGAACATGAGCATCATCGGC 
  
Table 1. TaqMan® gene expression assays for RT-qPCR. β-Actin used as the 
endogenous control reference gene. 
 
Data Analysis 
 All enzyme activities were calculated in terms of nmol/min/mg protein, and 
inhibition rates expressed as percent activity compared to the vehicle only control. 
Results from independent replicate assays were grouped and graphed using GraphPad 6 
software. PCR results were analyzed using the ΔΔCt method. Ct values below 16 and 
above 35 were removed from the results before any further calculations or analysis. Gene 
expression changes were normalized against the reference gene β-actin and are presented 
as relative fold change over vehicle control samples, all of which were complete culture 
medium with a 1% concentration of DMSO. Relative fold changes in gene expression 
were calculated using Microsoft Excel as 2-ΔΔCt for each target gene as follows: 
 ΔCt = Ct β-actin – Ct target 
 ΔΔCt =    ΔCt treatment – mean ΔCt vehicle control 





Results for each gene were grouped into related treatments for each of the three time 
points. Further statistical analyses were performed on each group using GraphPad Prism 
6 software by subjecting the data to a two-way ANOVA, followed by Tukey’s multiple 
comparisons test. The two-way ANOVAs were done to detect significant effects on gene 
expression changes based on treatment and exposure time. The Tukey’s multiple 
comparisons tests were carried out to compare the means of each treatment group within 











 The initial assays to quantify AChE and FAAH activity in various dilutions of cell 
supernatant demonstrated a protein concentration-dependent effect on the rates of 
hydrolysis for their respective substrates. Interestingly, the results from the data showed 
the activity rate of AChE as lower than that of FAAH in the cell supernatant samples, 
which is the opposite of what would typically be expected. Based on the results from 
inhibition assays performed by incubating cell supernatant with various concentrations of 
CPO prior to the assay, the most appropriate concentrations of CPO to use in treatment of 
cells for measurement of gene expression changes were determined to be 250 nM, 500 
nM, and 1 uM. Although the enzyme activity rates that were determined initially based 
on total protein concentrations in the absence of an inhibitor showed that FAAH activity 
was higher compared that of AChE in samples of similar protein content, the sensitivities 
to CPO inhibition were much more closely related in the corresponding CPO 
concentrations. Analysis of inhibition over time was necessary to ensure that FAAH was 
still being inhibited in the cells after such duration of exposure in culture to the same 
concentrations of CPO used to assess changes in target gene expression, and to 
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investigate the possible existence of any relationships between the levels of FAAH 
inhibition and expression of the target genes.  
 
 
Figure 3. Protein concentration-dependent rates of OMP hydrolysis to AMP. 
Supernatant dilutions were collected and total protein quantified as described in methods. 
Data are reported as mean ± SEM, n = 4. Linear regression analysis determined the rate 







Figure 4. Protein concentration-dependent rates of AChE hydrolysis of 
acetylthiocholine. Dilutions were made of the cell supernatant collected and total protein 
was quantified as described in methods. Data are shown as mean ± SEM, n = 4. Linear 
regression analysis determined the rate of hydrolysis was highly correlated with protein 
concentration (p = 0.001, r2 = 0.98). 
 
Data from figures 3 and 4 allowed selection of assay conditions for subsequent assays to 








Figure 5. Inhibition of FAAH in cell supernatants. The supernatant, collected as 
described in methods, was incubated at 37o C with a range of concentrations of 
chlorpyrifos oxon for 20 minutes prior to assay of residual activity at 37o C. Data are 









Figure 6. Inhibition of AChE in cell supernatants. The supernatant, collected as 
described in methods, was incubated at 37o C with a range of concentrations of 
chlorpyrifos oxon for 20 minutes prior to assay of residual activity at 37o C. Data are 
expressed as mean (± SEM of the percent of control activity, n = 3 independent assays). 
 
The in vitro inhibition data presented in figures 5 and 6 suggest that both FAAH and 
AChE would be markedly inhibited by CPO at concentrations higher than 100 nM. These 







Figure 7. FAAH inhibition in cells exposed while in culture. Data expressed as mean 












Figure 8. AChE inhibition in cells exposed while in culture. Data expressed as mean ± 
SEM of the percent of control activity (n = 3). 
 
As shown in figures 7 and 8, both FAAH and AChE were inhibited by CPO at the 
concentrations selected. Moreover, more extensive inhibition of both enzymes was with 
the highest concentration at the earlier time points (8 hours and 1 day). By 3 days of 









 We selected three concentrations of CPO eliciting concentration-related 
increasing FAAH inhibition to study effects on expression of representative genes 
regulated by PPARα and PPARγ. An exogenous ligand (AEA or OEA) was added to 
evaluate the interactive effects of CPO and the exogenous PPAR activator on gene 
expression. The following figures show concentration and time-dependent effects of CPO 
on expression of LXRα, ACOX1, AGPAT2, and ABCG2. 
LXRα 
 Figure 9 shows the effects of CPO alone on LXRα expression after 8 hours, 1 day, 
and 3 days of exposure in culture. There was a significant main effect of both CPO (F4,18  
= 606, p < 0.001) and time (F2,18 = 79, p < 0.001), as well as a significant interaction (F4,18 
= 112, p < 0.001). Pairwise comparisons across concentrations indicated significant 
differences within each time point for cells treated with CPO. In general, there was a 
step-wise, concentration-dependent increase after 8 hours, 1 day, and 3 days of exposure, 
and a significant increase with 1,000 nM CPO at all three time-points.  
 Figure 10 shows the effects of AEA (3 µM) alone or in the presence of CPO on 
LXRα expression. There was a significant main effect of treatment (F3,24 = 13.35, p < 
0.0001) and time (F2,24 = 33.49, p < 0.0001), as well as a significant interaction (F6,24 = 
8.846, p < 0.0001). AEA increased LXRa expression (4.5-6 fold) after 24 and 72 hours of 
exposure. Pairwise comparisons indicated significant differences between AEA alone and 
AEA in the presence of 250 and 1,000 nM CPO as well as AEA in the presence of 1000 
nM CPO compared to the lower CPO concentrations after 24 hours exposure. 
29 
 
 Finally, in the exogenous agonist OEA alone or OEA plus CPO, there was a 
significant main effect of the treatments (F3,24 = 42.04 ; p < 0.0001), and time (F2,24 = 
11.35 ; p = 0.0003), as well as a significant interaction (F6,24 = 11.35 ; p < 0.0001).  OEA 
alone, as well as in the presence of CPO, had relatively little effect at any time point 
except with the highest concentration of CPO. In that case, the greatest increases (5-10 















Figure 9. Effects CPO alone on LXRα expression. Relative fold change in expression 
of LXRα over vehicle control after exposure to CPO are shown. Data are presented as 
mean ± SD. At 8 hours after dosing, a single asterisk indicates a significant difference 
compared to 250 nM whereas a double asterisk indicates a difference compared to 500 
nM CPO. At 1 day after dosing, a pound sign indicates a significant difference compared 
to 250 nM while a double pound sign indicates a difference from 500 nM CPO. At 3 
days, a single dollar sign indicates a significant difference compared to 250 nM whereas 
a double dollar sign indicates a difference compared to 500 nM CPO. 
 
In general, CPO elicited a concentration-and time-dependent increase in LXRα 
expression. At 8 hours, a step-wise concentration-dependent increase was noted while at 
1 and 3 days, lower fold increases were noted except with the highest concentration.  
Thus, the changes noted at 8 hours suggested that this time may be best for evaluating 




Figure 10. Effects of CPO in the presence of AEA on LXRα expression. Relative fold 
change in expression of LXRα over vehicle control after exposure to AEA in the 
presence of CPO is shown. Data represent mean ± SD. At 1 day after dosing, a pound 
sign indicates a significant difference compared to 250 nM, and a double pound sign 
indicates a difference compared to 500 nM. 
 
AEA alone increased LXRα expression about 6-fold at the 1 day time-point. In the 
presence of 250 nM CPO however, no significant increase was noted at 1 day, or the 
other time-points. With the highest CPO concentration, the greatest fold increase was also 






Figure 11. Effects of CPO in the presence of OEA on LXRα expression. Data are 
presented as mean ± SD. A single asterisk at the 8 hour time point indicates a significant 
difference compared to 250 nM whereas a double asterisk indicates a significant 
difference compared to 500 nM, and a triple asterisk indicates a difference from OEA 
combined with 1000 nM CPO. At 1 day after dosing, a pound sign indicates a significant 
difference compared to 250 nM while a double pound sign indicates a difference 
compared to 500 nM. 
 
Similar to results evaluating the interactive effects of AEA and CPO, OEA had 
differential effects on LXRα expression when CPO was included. This interaction 
appeared blocked when the highest CPO concentration was used. Again, the greatest 





8 Hours 1Day 3 Days 
AEA 0.12 ± 0.01 5.81 ± 0.35 4.15 ± 1.20 
OEA 2.48 ± 0.39 1.11 ± 0.02 2.10 ± 0.05 
 
Table 2. Effects of exogenous agonists AEA and OEA on LXRα expression in MCF-
7 cells. Data are presented as mean relative fold change over vehicle only control, ± SD, 




 Figure 12 shows the effects of CPO alone on expression of ACOX1, another gene 
under the control of PPARα. There was a significant main effect of both CPO (F2,18 = 
975.9, p < 0.0001), and time (F2,18 = 1102.0, p < 0.0001), as well as a significant 
interaction (F4,18 = 345.2, p < 0.0001). In general, CPO caused marked increases in 
ACOX1 expression, with the most substantial effects being noted at the earliest time-
point (up to 55-fold with 1000 nM CPO). Pairwise comparisons across CPO 
concentrations indicated significant differences within each time- point. 
 We also evaluated the effects of the exogenous ligand AEA, in the presence and 
absence of CPO, on ACOX1 expression. AEA is a PPAR gamma agonist. Again, a main 
effect of treatment (F3,24 = 117.9, p < 0.0001), and time (F2,24 = 67.96, p < 0.0001) was 
noted, as well as a significant interaction (F6,24 = 67.96, p < 0.0001). A time-dependent 
increase in ACOX1 expression was noted with AEA alone at 1-3 days of exposure (4-8 
fold). Pairwise comparisons across all treatments indicated significant differences within 
each time point. CPO (500 and 1000 nM) increased ACOX1 expression relative to AEA 
alone at 24 hours of exposure. 
 Figure 14 shows the effects of OEA in the presence or absence of CPO on 
ACOX1 expression. OEA is a selective PPARα agonist, so little effect was expected. 
There was a significant main effect of treatment (F3,24 = 1747.0, p < 0.0001) and time 
(F2,24 = 140.5, p < 0.0001), however as well as a significant interaction (F6,24 = 199.9, p < 
0.0001). OEA alone did elicit relatively minimal increases (2-3 fold) at all three time-
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points. Pairwise comparisons suggested significant differences between OEA alone and 




















Figure 12. Effects of CPO on ACOX1 expression. Data are presented as mean relative 
fold change ± SD. At 8 hours after dosing, a single asterisk indicates a significant 
difference compared to 250 nM whereas a double asterisk indicates a difference from 500 
nM CPO. At 1 day after dosing, a pound sign indicates a significant difference compared 
to 250 nM while a double pound sign indicates a difference compared to 500 nM. Finally 
at 3 days after dosing, a dollar sign indicates a difference compared to 250 nM whereas a 











Figure 13. Effects of CPO in the presence of AEA on ACOX1 expression. Relative 
fold change in expression of ACOX1 over vehicle control after exposure to AEA plus 
concentrations of chlorpyrifos oxon in culture. Data are presented as mean ± SD. At 8 
hours after dosing, a single asterisk indicates a significant difference compared to 250 
nM. At 1 day after dosing, a pound sign indicates a significant difference compared to 
250 nM while a double pound sign indicates a difference compared to 500 nM. Finally at 
3 days after dosing, a dollar sign indicates a difference compared to 250 nM whereas a 










Figure 14. Effects of CPO in the presence of OEA on ACOX1 expression. Relative 
fold change in expression of ACOX1 over vehicle control after exposure to OEA plus 
concentrations of chlorpyrifos oxon in culture. Data are presented as mean ± SD. At 8 
hours after dosing, a single asterisk indicates a significant difference compared to 250 
nM, a double asterisk indicates a significant difference compared to 500 nM. At 1 day 
after dosing, a pound sign indicates a significant difference compared to 250 nM while a 
double pound sign indicates a difference compared to 500 nM. Finally at 3 days after 
dosing, a dollar sign indicates a difference compared to 250 nM, a double dollar sign 











8 Hours 1Day 3 Days 
AEA 0.03 ± 0.01 3.34 ± 0.29 8.28 ± 1.79 
OEA 2.98 ± 0.21 1.42 ± 0.09 1.38 ± 0.12 
 
Table 3. Effects of exogenous agonists AEA and OEA on ACOX1 expression in 
MCF-7 cells. Data are presented as mean relative fold change over vehicle only control, 




 Among the samples from cells treated with CPO alone, there was a significant 
main effect of both CPO (F2,18 = 5.026,  p = 0.0184) and time (F2,18 = 12.17, p = 0.0005), 
however, no significant interaction was noted (F4,18 = 0.533, p = 0.7133). Pairwise 
comparisons across concentrations revealed a significant difference with 1000 nM CPO 
after 1 day of exposure. 
 Additionally, there was a significant main effect of treatment (F3,24 = 245.5, p < 
0.0001), and time (F2,24 = 722.9, p < 0.0001), as well as a significant interaction (F6,24 = 
142.7, p < 0.0001) for cells treated with AEA only or a combination of AEA and one of 
the three concentrations of CPO. Pairwise comparisons indicated significant differences 
among all treatments at 1 day after dosing. The comparisons also determined significant 
differences between AEA plus 1000 nM CPO and all other treatments among all three 
durations of exposure. 
 Finally, in the cells that were treated with OEA alone or a combination of OEA 
and of three CPO concentrations, there was a significant main effect of treatment (F3,24 = 
67, p < 0.0001), and time (F2,24 = 118, p < 0.0001), as well as a significant interaction 
(F6,24 = 29, p < 0.0001). Pairwise comparisons determined significant differences between 
OEA alone and all other treatments within the 8 hours exposure period, as well as 1000 






Figure 15. Effects of CPO on AGPAT2 expression. Relative fold change in expression 
of AGPAT2 over vehicle control with exposure to CPO alone. Data are presented as 
mean ± SD. At 1 day after dosing, a pound sign indicates a significant difference 













Figure 16. Effects of CPO in the presence of AEA on AGPAT2 expression.  Data are 
presented as mean relative fold change in gene expression ± SD. At 1 day after dosing, a 
pound sign indicates a significant difference compared to 250 nM while a double pound 
sign indicates a difference compared to 500 nM. Finally at 3 days after dosing, a dollar 
sign indicates a difference compared to 250 nM, a double dollar sign indicates a 









Figure 17. Effects of CPO in the presence of OEA on AGPAT2 expression.  Relative 
fold change in expression of AGPAT2 over vehicle control after exposure to OEA plus 
concentrations of chlorpyrifos oxon in culture. Data are presented as mean ± SD. At 8 
hours after dosing, a single asterisk indicates a significant difference compared to 250 
nM, and a double asterisk indicates a significant difference compared to 500 nM. At 1 
day after dosing, a pound sign indicates a significant difference compared to 250 nM 











8 Hours 1Day 3 Days 
AEA 0.27 ± 0.02 4.53 ± 0.68 8.411 ± 0.70 
OEA 0.58 ± 0.05 5.01 ± 0.36 0.27 ± 0.01 
 
Table 4. Effects of exogenous agonists AEA and OEA on AGPAT2 expression in 
MCF-7 cells. Data are presented as mean relative fold change over vehicle only control, 




 There was a significant main effect of both CPO (F2,18 = 494.2, p < 0.0001), and 
time (F2,18 = 254.2, p < 0.0001), as well as a significant interaction (F4,18 = 147.8, p < 
0.0001) found in the samples from cells that were treated only with chlorpyrifos oxon. 
Pairwise comparisons across concentrations indicated significant differences within each 
time point, with the exception of no difference of significance between 250 nM and 500 
nM CPO 8 hours after dosing. 
 Among those samples from cells treated with either AEA only, or a combination 
of AEA and CPO, there was a significant main effect of the treatments (F3,24 = 30.29, p < 
0.0001), and time (F2,24 = 26.66, p < 0.0001), as well as a significant interaction (F6,24 = 
12.03, p < 0.0001). Pairwise comparisons across all treatments did not determine any 
significant differences within the 8 hours after dosing time point, but did indicate 
significant differences between AEA combined with 1000 nM CPO and all other 
treatments at 1 day after dosing, and that AEA alone and AEA in addition to 1000 nM 
CPO were both significantly different compared to 250 nM CPO plus AEA at 3 days 
after dosing. 
 Lastly, for the cells treated with only OEA or OEA plus one of the three CPO 
concentrations, there was a significant main effect treatment (F3,24 = 2378, p < 0.0001), 
and time (F2,24 = 299, p < 0.0001), as well as a significant interaction (F6,24 = 372, p < 
0.0001). Pairwise comparisons across all treatments determined significant differences 
between OEA alone and all other treatments within the 8 hours after dosing period, as 
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well as 1000 nM CPO combined with OEA to be significantly different compared to all 




















Figure 18. Effects of CPO on ABCG2 expression. Relative fold change in expression 
of ABCG2 over vehicle control after exposure to CPO alone. Data are presented as mean 
± SD. At 8 hours after dosing, a single asterisk indicates a significant difference 
compared to 250 nM whereas a double asterisk indicates a difference from 500 nM CPO. 
At 1 day after dosing, a pound sign indicates a significant difference compared to 250 nM 
while a double pound sign indicates a difference compared to 500 nM. Finally at 3 days 
after dosing, a dollar sign indicates a difference compared to 250 nM whereas a double 










Figure 19. Effects of CPO in the presence of AEA on ABCG2 expression.  Relative 
fold change in expression of ABCG2 over vehicle control after exposure to AEA plus 
concentrations of chlorpyrifos oxon in culture. Data are presented as mean ± SD. At 1 
day after dosing, a pound sign indicates a significant difference compared to 250 nM 
while a double pound sign indicates a difference compared to 500 nM. At 3 days after 











Figure 20 . Effects of CPO in the presence of OEA on ABCG2 expression.  Relative 
fold change in expression of ABCG2 over vehicle control after exposure to OEA plus 
concentrations of chlorpyrifos oxon in culture. Data are presented as mean ± SD. At 8 
hours after dosing, a single asterisk indicates a significant difference compared to 250 
nM, and a double asterisk indicates a significant difference compared to 500 nM. At 1 
day after dosing, a pound sign indicates a significant difference compared to 250 nM 
while a double pound sign indicates a difference compared to 500 nM. Finally at 3 days 
after dosing, a dollar sign indicates a difference compared to 250 nM, a double dollar 





8 Hours 1Day 3 Days 
AEA 0.25 ± 0.01 6.28 ± 0.32 9.31 ± 4.48 
OEA 1.55 ± 0.07 0.44 ± 0.01 1.37 ± 0.80 
 
Table 5. Effects of AEA and OEA on ABCG2 expression in MCF-7 cells. Data are 













The widespread use of organophosphorus (OP) pesticides is not going away 
anytime soon. They are efficacious, effective, budget-friendly, and easy to use in their 
many applications, providing a wide range of benefits to quality of life. Extensive risk 
assessments and periodic reevaluation have demonstrated that such chemicals can 
generally be used safely (36). Many of the more hazardous OP pesticides have been 
removed from use over the last 25 years or so (6). Certain usage restrictions have been 
imposed based on new data but, overall, chlorpyrifos and other OP pesticides have 
proven to be both effective and safe. However, it is necessary to examine how these 
chemicals may impact our health in ways that are not life-threatening or of immediate 
concern, as part of making sure that benefits continue to outweigh the risks.  Despite 
many investigations into toxicological effects potentially independent of 
acetylcholinesterase inhibition, there is still much to be learned.  
 One non-acetylcholinesterase target for OP anticholinesterases that may be 
particularly important is fatty acid amide hydrolase (FAAH). FAAH is the primary 
enzyme responsible for inactivation of the endocannabinoid anandamide, as well as 
52 
 
endocannabinoid- like metabolites. A number of studies have reported that FAAH is very 
sensitive to inhibition by CPO and other OP toxicants. 
 We hypothesized that inhibition of FAAH by CPO would allow endogenous lipid 
metabolites (AEA, OEA and/or PEA) to increase activation of PPARs, leading to 
increased transcriptional activity. We also proposed that the effects of exogenous PPAR 
agonists would be increased by CPO. Figure 21 illustrates the proposed mechanism by 
which this could occur. . 
 
 
Figure 21. Proposed pathway linking OP exposure to altered expression of PPAR 
target genes. 
Overall, our results showed an upregulation of all selected target genes by CPO. In 
general, concentration-dependent effects of CPO were noted, with the highest 
concentration generally causing the greatest increase. Although we predicted that 
expression changes would occur primarily due to AEA and OEA binding to PPAR, the 
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results showed that exposure to chlorpyrifos alone also caused significant increases in 
expression of the target genes. Interestingly, exposure time appeared to differentially 
affect expression changes among the four genes. AGPAT2 followed most closely our 
expectations i.e., more extensive changes with greater FAAH inhibition. As FAAH 
inhibition was greater at the 8 hours and 1 day time point, with substantial recovery at 3 
days, we initially expected greater transcriptional changes at the earlier time points.  
However, both ACOX1 and ABCG2 exhibited the opposite, with gene expression 
changes. The four genes were initially selected as specific targets for either PPARα 
(LXRα and ACOX1) or PPARγ (AGPAT2 and ABCG2). However, all four responded to 
both AEA and OEA exposure, so a clear distinction was not observed in isoform 
specificity in regulation of the genes in this study. What may be most important however, 
were the CPO concentration-dependent effects. These data suggest that there is, in fact, a 
dose-dependent effect on expression changes of at least some PPAR target genes. Such 
conclusions would be strengthened by performing more experiments with additional 
genes, followed by investigations that would assist in determining if there are any actual 
consequences of altered gene expression that could alter physiological function.  
Future studies need to be conducted in order to evaluate the physiologic impact of 
the altered gene expressions that were demonstrated by this study to examine effects on 
such functions as lipid metabolism. Additional in vitro experiments to investigate 
whether, or not, the observed increased gene expression corresponds to an increase in 
protein translation are an important step in determining the possible consequences of OP 
exposure-related PPAR signaling changes. For example, analyses of cell lipid content 
changes could strengthen conclusions regarding the functional changes associated with 
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altered gene expression.  Such studies could lead to an adverse outcome pathway to 
describe mechanisms for potential real-life consequences of chronic, low-dose 
environmental exposure to chlorpyrifos.  
The U.S. Centers for Disease Control and Prevention (CDC) National Center for 
Health Statistics (NCHS) ranks heart disease as the number one cause of death in the 
United States, with a mortality rate of over 600,000 deaths in 2017 (62). Data from the 
NCHS 2018 summary reported that roughly 44% of all adults, ages 18 and older, suffer 
from some form of circulatory  compromise, including coronary heart disease and 
hypertension. High concentrations of plasma cholesterol are a well-known risk factor in 
the development of cardiovascular disease. As a key regulator of plasma cholesterol 
levels, as well as intracellular cholesterol, and intestinal cholesterol absorption, 
dysfunctional expression of LXRα could potentially be a contributor to the ever-
increasing incidence of cardiac complications (52,53). Additionally, overexpression of 
LXRα has been demonstrated to inhibit PPAR binding to RXR, therefore it could also 
play a role in metabolic disorders by interfering with the roles of PPARs in their 
regulation of such functions (52,53,63).  
  The CDC’s National Center for Chronic Disease Prevention and Health 
Promotion estimated in their 2017 report that nearly 10% of the total population of the 
United States has struggle with diabetes, based on the numbers of known diagnosed to be 
23.1 million, and an additional 7.2 million undiagnosed (64). Type 2 diabetes accounts 
for over 90% of all cases (65). These numbers do not even include the estimated 33.9% 
of adults aged 18 and older that have been reported to be diagnosed with prediabetes 
(2015 data). Overexpression of AGPAT2 has been shown to increase triaglycerol 
55 
 
accumulation in the liver, and is a known contributor to development of hepatic steatosis 
and severe insulin resistance (56,57).    
 The physiological roles of ABCG2 vary based on tissue-specific location and 
levels of expression. In all cases, however, ABCG2 is a critical component in regulation 
of xenobiotic transport both into, and out of, the cells, thereby playing a dual part in 
protection from toxicants by not allowing absorption, and in homeostasis of cellular 
functions based on retention or efflux of compounds it transports (58,59). Disruption in 
normal expression levels of ABCG2 can lead to a number of complications related to 
xenobiotic absorption and clearance, including altered efficacy of drugs, by increased 
toxicity due to retention, or even no effect at all, due to resistance to absorption (58).  
 Continued investigation into the effects of chronic exposure to OP pesticides on 
non-target organisms and human health is a necessary part of ensuring that the most 
responsible decisions can be made when it comes to regulation and use of chemicals that 
we depend on for the protection of vital resources such as food crops, and for the control 
and prevention of life-threatening diseases spread by target insects like mosquitos and 
ticks. Although OPs have been extensively studied since they were first synthesized, and 
careful consideration to detail is made throughout risk assessments in terms of 
registration and regulation for use in all of their applications, ongoing re-evaluations are 
important in building the most comprehensive knowledge about such chemicals and their 
effects on the broader population, in different doses, and over longer periods of time than 
those typically applied to initial risk assessments and regulatory decisions as their result. 
While the target genes used in this study, and their representative roles in metabolic 
functions and disorders are only a miniscule portion of the human metabolome, the 
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information gathered from these data help to provide a small piece to the much larger 
puzzle in characterizing the molecular mechanisms in which human health can be 








SUMMARY AND CONCLUSIONS 
 
 Both FAAH and AChE in MCF-7 cells were inhibited by CPO in a concentration-
dependent manner in vitro and in culture.  
 The expression of four selected genes associated with PPAR signaling showed 
concentration-dependent increases with CPO exposure. 
 Changes in gene expression by CPO could be mediated by FAAH inhibition, 
leading to PPAR activation by endogenous agonists. In contrast, CPO could act as 
a direct PPAR agonist. Both of these pathways need further investigation.  
 The expression of all four target genes was upregulated with the highest 
concentration of CPO (1000 nM) when either of the exogenous agonists (AEA or 
OEA) was included. 
 No target gene specificity between PPARα and PPARγ was noted with the 
exogenous agonists used. 
 Gene expression changes appeared to support the hypothesis that FAAH 
inhibition allows for increased AEA and OEA binding to PPAR, leading to 




 Additional experiments to investigate corresponding increases in protein products 
and functional endpoints such as accumulation would strengthen our results.  
 Overall, the data suggest a potential link between OP pesticide exposure and 
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